Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

As the DNA testing company 23andMe prepares for a potential sale, Congress is demanding answers on data privacy concerns.

Lawmakers are raising questions about how the company handles and protects sensitive genetic information of its customers.

There are concerns that the data collected by 23andMe could be misused or shared without the consent of the individuals.

Congress is seeking assurances that the privacy of genetic data will be safeguarded in any potential sale or partnership.

The sale of 23andMe could have significant implications for data privacy and the future of genetic testing.

Lawmakers are calling for transparency and accountability from the company to address these concerns.

There is also a push for stronger regulations to protect consumers’ genetic information in the rapidly evolving field of genetic testing.

Congressional hearings and investigations are expected to shed light on the data privacy practices of companies like 23andMe.

The outcome of these inquiries will shape the future of genetic testing and data privacy in the United States.

It remains to be seen how 23andMe will respond to the demands for answers and what impact this will have on the company’s potential sale.